Christie CounterAct to reduce pathogens in commercial indoor venues

KUALA LUMPUR, Oct 30 -- Christie® has launched the Christie® CounterAct™ line of commercial UV disinfection products with patented Care222® far-UVC light technology for cinemas, theme parks, museums, sports complexes and other indoor spaces.

Unlike comparable products, the Christie fixture uses Ushio’s patented narrowband filtered Care222 excimer lamps that emit far-UVC 222nm light - the only UV technology shown to continuously and significantly reduce pathogens, like coronaviruses.

It may also be used while people are present, when used in accordance with specified parametres. Mass production of the new Christie CounterAct fixture starting January, next year.

Developed by Christie’s parent company, Ushio Inc, based on technology licensed from Columbia University, the revolutionary Care222 far-UVC, mercury-free excimer lamp includes a proprietary short pass filter that prevents the emission of longer wavelengths of UV light (230nm and higher) that are capable of penetrating human skin and eyes.

“The fact that far-UVC light – specifically, our new Christie CounterAct far-UVC fixture – can be used in the presence of people is a real differentiating factor,” said Christie president and COO, Zoran Veselic.

“By harnessing these benefits as part of a user-friendly product that can be quickly deployed, we hope to provide a much-needed boost to our partners across the entertainment industry who are currently struggling to attract wary customers.”

According to a statement, Christie CounterAct is a line of fixtures that are simple to control remotely and can be installed on ceilings as easily as a commercial lighting fixture.

It is well suited for use across a wide range of occupied, commercial areas such as entertainment venues, including lobbies, auditoriums and restrooms.

-- BERNAMA